Overview

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Status:
Terminated

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

This study will compare the safety and efficacy of sunitinib in combination with prednisone versus placebo and prednisone in patients that have metastatic castration-resistant prostate cancer that has progressed after treatment with a docetaxel-containing chemotherapy regimen. This is a second-line study.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Docetaxel
Prednisone
Sunitinib